XML 12 R2.htm IDEA: XBRL DOCUMENT v3.19.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Mar. 31, 2019
Jun. 30, 2018
 [1]
Current assets:    
Cash and cash equivalents $ 84.9 $ 110.9
Marketable investment securities 64.8 69.7
Prepaid expenses 11.3 9.4
Inventory 31.9 34.3
Trade accounts receivable 142.6 99.5
Prepaid taxes 3.0  
Other receivables 4.4 3.8
Total current assets 342.9 327.6
Property, plant and equipment, net 58.7 43.2
Long-term marketable investment securities 40.3 30.7
Intangibles, net 699.5 455.2
Goodwill 415.9 318.6
Total assets 1,557.3 1,175.3
Current liabilities:    
Accounts payable 24.1 26.0
Accrued liabilities 78.8 68.3
Short-term contingent consideration 3.7 5.3
Deferred revenue 2.3 2.6
Total current liabilities 108.9 102.2
Unrecognized tax benefits 19.9 24.9
Other long-term liabilities 7.3 6.3
Contingent consideration 10.3 9.2
Long-term debt 263.4 9.3
Long-term deferred taxes 65.8 57.3
Total liabilities 475.6 209.2
Commitments and contingencies
Stockholders’ equity:    
Common stock, 73.4 and 70.6 shares outstanding at March 31, 2019 and June 30, 2018 respectively 0.7 0.7
Additional paid-in capital 1,057.0 915.4
Accumulated other comprehensive loss (5.7) (4.1)
Retained earnings 29.8 54.1
Total Myriad Genetics, Inc. stockholders’ equity 1,081.8 966.1
Non-Controlling Interest (0.1)  
Total stockholders' equity 1,081.7 966.1
Total liabilities and stockholders’ equity $ 1,557.3 $ 1,175.3
[1] Amounts adjusted due to the adoption of Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (Topic 606). See Note 1 to the financial statements contained in Part I, Item 1 of this report for additional information.